NAMD’s Recommendations on CMS’ Prescription Drugs Prior Authorization Interoperability Proposed Rule
This resource provides a high-level summary of NAMD’s comments on the 2026 CMS’ Interoperability Standards and Prior Authorization...
Letter ·
NAMD Comments on the 2026 CMS’ Interoperability Standards and Prior Authorization for Drugs Proposed Rule
On June 15, 2026, NAMD formally commented on CMS’ Interoperability Standards and Prior Authorization for Drugs Proposed Rule.
On June 15, 2026, NAMD submitted comments on CMS’ proposed rule, 2026 CMS Interoperability Standards and Prior Authorization for Drugs (CMS-0062-P).
NAMD supports CMS’ goals of improving interoperability, streamlining prior authorization processes, and promoting informed decision-making through the exchange and use of health information. However, Medicaid agencies have concerns about the feasibility of implementing the proposed requirements on CMS’ timeline while also managing major systems and policy changes, budget constraints, procurement processes, and implementation of prior interoperability rulemaking.
To support successful implementation and advance the intended goals of the rule, CMS should extend the implementation period and provide Medicaid agencies with tailored technical assistance and other implementation resources.
Read NAMD’s full comments here.
Related resources
Why Did They Do It That Way? Prescription Drugs
Does Medicaid cover prescription drugs? Under federal law, coverage of prescription drugs through the Medicaid program is an...
Q&A with Gary Smith: Leading Medicaid in the U.S. Virgin Islands
Gary Smith has served as Medicaid Director for the U.S. Virgin Islands for the past eight years. In...
Stay Informed
Drop us your email and we’ll keep you up-to-date on Medicaid issues.